413 related articles for article (PubMed ID: 19553377)
1. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.
Yang DH; Chang DM; Lai JH; Lin FH; Chen CH
Rheumatology (Oxford); 2009 Sep; 48(9):1083-7. PubMed ID: 19553377
[TBL] [Abstract][Full Text] [Related]
2. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
[TBL] [Abstract][Full Text] [Related]
3. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Manzi S; Navratil JS; Ruffing MJ; Liu CC; Danchenko N; Nilson SE; Krishnaswami S; King DE; Kao AH; Ahearn JM
Arthritis Rheum; 2004 Nov; 50(11):3596-604. PubMed ID: 15529364
[TBL] [Abstract][Full Text] [Related]
4. Platelet C4d is highly specific for systemic lupus erythematosus.
Navratil JS; Manzi S; Kao AH; Krishnaswami S; Liu CC; Ruffing MJ; Shaw PS; Nilson AC; Dryden ER; Johnson JJ; Ahearn JM
Arthritis Rheum; 2006 Feb; 54(2):670-4. PubMed ID: 16447243
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Singh V; Mahoney JA; Petri M
J Rheumatol; 2008 Oct; 35(10):1989-93. PubMed ID: 18709693
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
7. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
8. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
9. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA
Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
[TBL] [Abstract][Full Text] [Related]
11. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia in males with systemic lupus erythematosus.
Mok CC; Lau CS; Lee KW; Wong RW
J Rheumatol; 1998 Dec; 25(12):2357-63. PubMed ID: 9858430
[TBL] [Abstract][Full Text] [Related]
13. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
14. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.
Batal I; Liang K; Bastacky S; Kiss LP; McHale T; Wilson NL; Paul B; Lertratanakul A; Ahearn JM; Manzi SM; Kao AH
Lupus; 2012 Jan; 21(1):13-26. PubMed ID: 21959138
[TBL] [Abstract][Full Text] [Related]
17. Correlation of serum measures of nitric oxide production with lupus disease activity.
Gilkeson G; Cannon C; Oates J; Reilly C; Goldman D; Petri M
J Rheumatol; 1999 Feb; 26(2):318-24. PubMed ID: 9972965
[TBL] [Abstract][Full Text] [Related]
18. Glomerular c4d staining can be an indicator of disease activity in lupus nephritis.
Sahin OZ; Gurses S; Taslı F; Yavas H; Ersoy R; Uzum A; Cirit M
Ren Fail; 2013; 35(2):222-5. PubMed ID: 23176021
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
20. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
